

# Meta-analysis of Acupuncture Combined with Cognitive Rehabilitation Training in the Treatment of Cognitive Impairment after Stroke

Shuangjuan Liu<sup>1</sup>, Yingying Hu<sup>1</sup>, Ximei Xie<sup>1,2\*</sup>

<sup>1</sup>School of Acupuncture and Tuina, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China

<sup>2</sup>Xi'an Hospital of Traditional Chinese Medicine, Acupuncture Department, Xian, Shaanxi, China <sup>\*</sup>corresponding author

*Keywords:* Acupuncture, Cognitive Rehabilitation Training, Cognitive Impairment after Stroke, Meta-Analysis

*Abstract:* To systematically review the clinical efficacy and safety of acupuncture combined with rehabilitation training in the treatment of post-stroke cognitive impairment (PSCI). Chinese and English databases such as CNKI, Wanfang database, CBM, PubMed, Embase and The Cochrane Library were searched for randomized controlled trials of acupuncture combined with rehabilitation training in the treatment of PSCI. RevMan 5.4 was used to evaluate the quality of the literature and Meta analysis. Publication bias was determined by Egger test and funnel plot. A total of 30 RCTS were included with 2506 participants. The results of Meta-analysis showed that acupuncture combined with rehabilitation training was superior to the single treatment group in improving the effective rate, increasing the Montreal cognitive assessment (MoCA) score and BI index, reducing P300 delay and increasing P300 amplitude. Acupuncture combined with rehabilitation training has significant clinical effect in the treatment of PSCI, and the combination of the two has synergistic effect, and it is worthy of further study and discussion.

## 1. Introduction

Stroke is the chief reason of death and disability worldwide, with an epidemiological survey showing a global prevalence of 101 million people [1]. Post-stroke cognitive dysfunction (PSCI) refers to a clinical syndrome that reaches the standard within 6 months after the occurrence of cerebrovascular accidents, and is mainly manifested as visuospatial, orienting, calculating, memory and other disorders [2]. There is data reports that about 1/3 of stroke patients had cognitive dysfunction [3], and the prevalence of PSCI was as high as 40% [4] and PSCI could also induce

Copyright: © 2023 by the authors. This is an Open Access article distributed under the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (https://creativecommons.org/licenses/by/4.0/).

stroke recurrence [5] .Since PSCI is the result of multiple factors, single therapy can not achieve satisfactory curative effects so the multi-mode intervention strategy has received special attention.

With people's attention to combined therapy, a good deal of clinical studies about acupuncture combined with cognitive training have appeared in recent years. Previous studies have found that compared with single treatment, acupuncture combined therapy has the advantages of alleviating adverse reactions, high patient compliance, good long-term efficacy and cost saving [6,7]. Although a Meta study [8] showed that acupuncture combined with cognitive training had better efficacy than acupuncture alone, it was published a long time ago, and there were few studies included, with limited reference value. Based on this, we hope to analyze the efficacy of acupuncture combined with cognitive training in the treatment of PSCI through statistical methods, further provide the latest evidence-based medical evidence and provide reference for clinical treatment.

## 2. Materials and Methods

## 2.1. Inclusion and Exclusion Criteria

The inclusion criteria were as follows: (1)type of studies: RCTs;(2)patients with clinically diagnosed PSCI;(3)The experimental group received acupuncture combined with cognitive training, while the control group received acupuncture or cognitive training alone, and the basic drugs of the two groups must be similar.(4)The main outcome measurements:included effective rate, MoCA;Secondary outcomes included Auditory Event-related Potential (P300) and Barthel index.

The following exclusion criteria were applied: (1) Intervention methods include moxibustion, traditional Chinese medicine, cupping, eye acupuncture, ear acupuncture and other therapies; (2) republished studies, full text unavailable or incomplete data; (3) Studies with unclear diagnosis or no relevant outcome indicators; (4) Mechanism studies, cases, reviews, guidelines and other non-clinical randomized controlled trials; (5) Study grouping was inappropriate, or cognition impairment caused by other diseases except for stroke.

## **2.2. Identification of Eligible Trials**

We searched the Embase, PubMed, CBM,CNKI, Wanfang, VIP, and Cochrane Library in English and Chinese published on or before November, 2021.The search terms included "stroke", "cognitive impairment", "cerebrovascular accident," "cerebrovascular apoplexy," "brain vascular accident," "cognitive dysfunction ", "Mild Neurocognitive Disorder", "acopuncture", "Electroacupuncture", "scalp acupuncture ", etc.

#### **2.3. Risk of Bias**

For the included studies, RevMan 5.4, a risk bias assessment tool of the Cochrane Collaboration Network, was used for bias assessment. The relevant contents are as follows: (1) Random method; (2) allocation concealment; (3) blinding of participants ;(4)blinding of outcome assessment;(5) whether the result data is complete; (6) Selective reporting;(7)other bias. If there is disagreement in the evaluation process, the third researcher will be consulted to make a decision. The findings were classified as high, low, or undefined risk of bias.

#### **2.4. Data Extraction**

Two researchers independently screened the results according to the inclusion and exclusion criteria. If there is a dispute, a third researcher will participate in the discussion until a consensus is

reached. A self-designed data collection table was used to extract information from the final included studies, authors, publication time, diagnostic criteria, outcomes, course of treatment, adverse events, weighted.

## **2.5. Statistical Analysis**

The Cochrane Review Manager version 5.4 software was used for evaluate the quality of the literature and Meta analysis. Measurement data were presented as weighted mean differences, and count data were presented as risk ratio, meanwhile P < 0.05 was considered significant. When  $I^2 \leq 50\%$ , the studies will adopt fixed-effects model. If  $I^2 > 50\%$  significant heterogeneity was considered among the studies and random-effects model was adopted. When the number of articles is more than 10, we will use funnel chart to analyze the publication bias.

## 3. Results

#### **3.1. Eligible Studies**

The workflow of literature screening and inclusion is shown in Figure 1. According to the search strategy, a total of 2571 literatures were obtained from seven databases, and 1570 literatures remained after duplication removal. After initial screening, 1481 articles were excluded. 89 studies were excluded because they did not meet inclusion criteria, 55 articles were deleted after browsing the full text. Ultimately 30 RCTS were included with a total of 2506 patients, aged between 35 and 80 years.




Figure 1. Literature screening flow diagram

#### 3.2. Assessment of Risk of Bias

The 30 studies included all referred to "random assignment", but nine of them did not report the method of generating the randomized sequence in detail, so they were considered to be high-risk. Only 2 studies mentioned the implementation of allocation concealment using opaque sealed envelopes, so they were low risk. Two studies were blinded to the subjects and five studies were

blinded to the assessors and thus were low risk. All studies did not state whether there was selective reporting of results and other sources of bias, and were considered low risk Figure 2.




Figure 2. Risk of bias graph and summary

## **3.3.Effective rate**

A total of 15 studies reported effective rates, As heterogeneity test  $I^2 = 0\%$ , fixed effects model was adopted. The results suggested that acupuncture combined with cognitive training was superior to single therapy in the treatment of PSCI(RR=1.23, 95% CI:1.17 to 1.30], *P*<0.05,  $I^2 = 0\%$ ).

## **3.4.MoCA**

17 studies used MoCA to assess overall cognitive function, involving 1,431 patients. Heterogeneity test I2 =78%, so we chose the random effect model, the results suggest that acupuncture combined with cognitive training is better than single therapy in the treatment of PSCI(WMD=2.96, 95%CI:2.28 to 3.63, P<0.05,I2 =78%). In five aspects of attention, orientation, visuospatial and executive function, and language ability, the analysis of 4 studies showed that acupuncture combined with cognitive training was superior to single therapy, but for abstraction, there was no significant difference between the two (Figure 3).

Subscreption         Experimental         Control         Mean Difference         Mean Difference           3.1.4         Attention function         50         Total Mean         Mean Difference         Mean Difference           3.1.4         Attention function         50         Total Mean         0.17         0.16         0.30           Str. Attention function         0.27         0.28         0.47         0.020         0.27         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021         0.021	,				- (-	-0			
$ \begin{array}{c} \textbf{3.1.4 Attention function} \\ Ram 2020 \\ Ram 2020 \\ Weng 2021 \\ 2.07 0.23 100 3.47 0.23 100 3.40 0.27 90 7.4\% \\ Weng 2021 \\ 2.08 0.41 30 1.91 0.56 30 4.4\% \\ Weng 2021 \\ 2.09 0.41 30 1.91 0.56 30 4.4\% \\ Weng 2021 \\ 2.09 0.41 30 1.91 0.56 30 4.4\% \\ Weng 2021 \\ 2.09 0.41 30 1.91 0.56 30 4.4\% \\ Weng 2021 \\ 2.09 0.56 (D_{III} = 31.66, dI = 3.6^{\circ} = 0.0001); P = 00\% \\ \textbf{3.1.2 Orientation ability} \\ Ram 2020 \\ Weng 2021 \\ Sam 2020 \\ Weng 2021 \\ Sam 2020 \\ Sam 2021 \\ Sam 2020 \\ $	~					<b>T</b>		Mean Difference	Mean Difference
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Total	Mean	SD	Total	weight	IV, Random, 95% CI	IV. Random, 95% CI
$ \begin{array}{c} \text{Shi } 221 & 3.77 & 0.23 & 100 & 3.61 & 0.17 & 100 & 7.4\% & 0.26 & [0.20, 0.32] \\ \text{Wang } 223 & 2.29 & 0.41 & 100 & 169 & 0.59 & 0.48\% & 0.09 & [0.71, 123] \\ \text{Shitbotal } (95\% \text{ CD}) & 196 & 100 & 4.67 & 196 & 20.0\% & 0.59 & [0.24, 0.75] \\ \text{Hetergenetik, Tau"a = 0.06, Chr = 31.66, dr = 3.0P < 0.00001; l = 90\% & 0.50 & [0.24, 0.75] \\ \text{Test for overall effect } 2 = 3.84 & (P = 0.0001) \\ \text{Shitbotal } (95\% \text{ CD}) & 5.9 & 0.49 & 0.26 & 36 & 6.7\% & 0.27 & [0.06, 0.46] \\ \text{Shitbotal } (95\% \text{ CD}) & 5.9 & 0.49 & 0.26 & 30 & 0.27 & [0.06, 0.46] \\ \text{Shitbotal } (95\% \text{ CD}) & 5.9 & 0.49 & 0.26 & 100 & 6.9\% & 0.27 & [0.06, 0.46] \\ \text{Shitbotal } (95\% \text{ CD}) & 5.9 & 0.67 & 100 & 4.69 & 0.26 & 100 & 6.9\% & 0.36 & [0.26, 0.47] \\ \text{Wang } 2021 & 6.44 & 1.37 & 30 & 4.16 & 1.63 & 30 & 1.0\% & 0.48 & [0.26, 0.671] \\ \text{Hetergenetik, Tau"a = 0.04; Chr = 1.168, dr = 3.0P = 0.0005; l = 74\% & 0.48 & [0.20, 0.371 & 1.61 & 103] \\ \text{Test for overall effect } 2 = 3.48 & (P = 0.0005) \\ \text{Shitbotal } (95\% \text{ CD}) & 3.09 & 146 & 30 & 151 & 5.26 & 100 & 13\% & 0.09 & [0.03, 1.173] \\ \text{Zhang } 2020 & 3.09 & 1.46 & 30 & 3.15 & 12.2 & 30 & 3.2\% & 0.09 & [0.33, 1.173] \\ \text{Zhang } 2020 & 4.37 & 0.61 & 30 & 3.05\% & 0.04 & [0.03, 0.31, 1.73] \\ \text{Zhang } 2020 & 4.37 & 0.61 & 30 & 3.05\% & 0.698 & [0.066, 1.12] \\ \text{Wang } 2020 & 4.37 & 0.61 & 30 & 1.77 & 0.43 & 30 & 6.2\% & 0.04 & [0.31, 0.53] \\ \text{Zhang } 2020 & 1.83 & 0.48 & 1.39 & 0.51 & 0.05\% & 0.04 & [0.31, 0.53] \\ \text{Zhang } 2020 & 2.65 & 108 & 2.14\% & 0.65 & 36 & 4.6\% & 0.43 & [0.16, 0.70] \\ \text{Zhang } 2020 & 2.65 & 108 & 2.14\% & 0.65 & 36 & 4.6\% & 0.43 & [0.16, 0.70] \\ \text{Zhang } 2020 & 2.65 & 108 & 2.14\% & 0.65 & 36 & 4.6\% & 0.43 & [0.16, 0.70] \\ \text{Zhang } 2020 & 2.65 & 108 & 2.24\% & 0.05 & 0.51 & 0.025 \\ \text{Zhang } 2020 & 2.65 & 108 & 2.24\% & 0.05 & 0.625 & 0.22 & [0.06, 0.50] \\ \text{Zhang } 2020 & 2.64 & 103 & 3.13 & 0.62 & 36 & 6.3\% & 0.43 & [0.16, 0.70] \\ \text{Zhang } 2020 & 364 & 0.43 & 0.13 & 0.62\% & 0.43 & [0.10, 10, 0.53] \\ Zhatbotal (6\%, CD) & 16\% & 176 & 1706 & 100 & 0.27\% & 0.$									
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$									
Subtrial (95% C) 106 107 106 107 106 107 107 107 107 107 107 107 107 107 107									
Heterogeneity: Tau" = 0.05; Ch" = 31.66, df = 3 (P = 0.0001); P = 90% Test for overall effect 2 = 3.84 (P = 0.0001) <b>3.1.2 Orientation ability</b> Ran 2020 Statutoral (25% Cf) Statutoral (25% Cf)		5.27 1.01		4.57	1.2				
Testfor overall effect $Z = 3.84$ (P = 0.0001) <b>3.1.2 Orientation ability</b> Ran 2020 Shi 2021 Subtoal (95% C) <b>3.1.3 Wissopatial dysfunction</b> <b>3.1.2 Wissopatial dysfunction</b> <b>3.1.3 Wissopatial dysfunction</b> <b>3.1.4 Distruct ability</b> <b>3.1.4 Missopatial dysfunction</b> <b>3.1.4 Missopatial dysfunction</b> <b>3.1.5 Missopatial dysfunction</b> <b>3.1.6 Missopatial dysfu</b>								0.50 [0.24, 0.75]	-
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				'= 3 (P <	0.000	01); P	= 90%		
Shi 2021 6.22 0.49 100 4.86 0.26 100 6.9% 0.36 [0.25, 0.47] Wang 2021 6.44 1.37 30 4.18 1.39 30 1.0% 1.76 (0.91, 2.61) Subtotal (95% Cf) 6.3 0.57 106 6.17 0.57 106 16.7% 0.46 [0.20, 0.71] Heterogeneity: Tau" = 0.04; ChP = 11.58, df = 3 (P = 0.009); P = 74% Test for overall effect $Z = 3.48 (P = 0.0005)$ 3.1.3 Vascospatial dysfunction/Kaccuthe function Ren 2020 3.88 1.46 36 3.15 1.52 36 1.4% 0.73 [0.04, 1.42] Shi 2021 4.51 1.44 100 3.11 1.44 000 3.0.9% 0.50 [0.31, 1.21] Zhang 2020 4.37 0.81 30 3.393 1.02 30 2.5% 0.54 [0.03, 1.01] Subtotal (95% Cf) 1.30 0.01 ChP = 1.38, df = 3 (P = 0.007); P = 75% Test for overall effect $Z = 5.57 (P = 0.0000)$ 3.1.4 Abstract ability Wang 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.65 [0.05, 1.12] Shi 2021 1.33 0.68 30 1.77 0.43 30 4.2% 0.04 0.01, 0.39] Wang 2021 1.83 0.68 30 1.77 0.43 30 4.2% 0.040 0.17, 0.39] Wang 2021 1.83 0.68 30 1.77 0.43 30 4.2% 0.047 [0.31, 0.39] Wang 2021 1.83 0.68 30 1.77 0.43 30 4.2% 0.047 [0.31, 0.63] Wang 2021 1.83 0.68 30 1.77 0.43 30 4.2% 0.047 [0.31, 0.63] Wang 2021 1.83 0.68 30 1.77 0.43 30 4.2% 0.047 [0.31, 0.63] Heterogeneity: Tau" = 0.09; ChP = 12.11, df = 3 (P = 0.007); P = 75% Test for overall effect $Z = 1.82 (P = 0.07)$ 3.1.5 Naming ability Test for overall effect $Z = 1.32 (P = 0.07); P = 75\%$ Test for overall effect $Z = 1.48 (P = 0.07)$ Shi 2021 2.73 0.55 100 2.26 0.55 100 5.2% 0.41 [0.50, 0.50] Heterogeneity: Tau" = 0.03; ChP = 12.11, df = 3 (P = 0.01); P = 73% Test for overall effect $Z = 2.48 (P = 0.07)$ Shi 2021 2.73 0.55 130 2.27 0.64 30 5.2% 0.41 [0.50, 0.50] Heterogeneity: Tau" = 0.03; ChP = 0.03; 0.27 30 0.45 30 0.45 [0.49 [0.50, 0.50] Heterogeneity: Tau" = 0.03; ChP = 0.02; P = 73% Test for overall effect $Z = 2.877 (P = 0.00001)$ Test for overall effect $Z = 2.877 (P = 0.00001)$ Test for overall effect $Z = 8.77 (P = 0.00001)$ Test for overall effect $Z = 2.877 (P = 0.00001)$ Test for overall effect $Z = 2.877 (P = 0.00001)$ Test for overall effect $Z = 8.77 (P = 0.00001)$ ; P = 73% Test for over									
Wang 2021       6.84       1.37       30       4.18       1.93       30       1.08       0.46 [0.07, 0.05]         Sharg 2026       6.63       0.66       1.08       0.31%       0.46 [0.07, 0.05]       0.46 [0.07, 0.05]         Heterogeneity, Tau"= 0.04; Ch"=11.68, df=3 (P = 0.0005); P= 74%       0.46 [0.20, 0.71]       0.46 [0.20, 0.71]       0.46 [0.20, 0.71]         Shi 2021       3.80       1.48       30       3.15       0.46 [0.20, 0.71]         Wang 2021       3.91       1.44       100       3.17       1.48       30       1.38       0.52 [0.31, 1.73]         Shi 2021       3.80       1.43       1.37       3.65       1.62       0.57 [0.06, 1.12]       0.57 [0.05, 1.01]         Shi 2021       4.19       1.33       30       1.76       0.59 [0.05, 1.12]       0.54 [0.05, 1.02]         Shi 2021       4.73       1.12       36       4.14       1.17       36       2.18       0.59 [0.05, 1.12]       0.54 [0.03, 0.63]         Shi 2021       4.72       1.23       100       4.66       166       0.58       0.54 [0.05, 0.56]         Shi 2021       1.72       0.56       156       1.68       0.54 [0.13, 0.65]       0.54 [0.02, 0.65]       0.54 [0.02, 0.65]       0.51 [0	Ran 2020	5.18 0.52	36	4.91	0.28	36	5.7%	0.27 [0.08, 0.46]	
$ \begin{array}{c} 2hang 2020 & 5.63 & 0.67 & 30 & 5.17 & 0.67 & 30 & 3.1\% & 0.46 [0.07, 0.65] \\ \text{Heterogeneity: Tayle 0.04; Chir = 11 50; dir = 3 (P = 0.000); P = 74\% & 0.46 [0.07, 0.65] \\ \text{Heterogeneity: Tayle 0.04; Chir = 11 50; dir = 3 (P = 0.000); P = 74\% & 0.46 [0.07, 0.65] \\ \text{S.1.3 Visuospatial dysfunction. Executive function \\ Fan 2020 & 3.88 & 1.46 & 36 & 3.15 & 1.52 & 30 & 1.4\% & 0.30 & 0.30 & 0.03; 1.21] \\ \text{Wang 2021 } & 4.19 & 1.31 & 30 & 3.17 & 1.48 & 30 & 1.3\% & 0.24 [0.07, 1.01] \\ \text{Subtatal (95% Cl)} & 3.83 & 1.02 & 30 & 2.5\% & 0.54 [0.07, 1.01] \\ \text{Subtatal (95% Cl)} & 1.73 & 0.46 & 1.05 & 100 & 3.9\% & 0.074 [0.48, 1.00] \\ \text{Subtatal (95% Cl)} & 1.73 & 0.46 & 1.05 & 100 & 3.9\% & 0.06 [0.34, 0.98] \\ \text{Wang 2021 } & 1.83 & 0.48 & 30 & 1.79 & 0.71 & 30 & 3.5\% & 0.06 [0.05, 1.12] \\ \text{Subtatal (95% Cl)} & 1.83 & 0.48 & 30 & 1.79 & 0.71 & 30 & 3.9\% & 0.06 [0.05, 1.12] \\ \text{Subtatal (95% Cl)} & 1.83 & 0.48 & 30 & 1.79 & 0.71 & 30 & 3.9\% & 0.06 [0.05, 1.12] \\ \text{Subtatal (95% Cl)} & 1.83 & 0.48 & 30 & 1.79 & 0.71 & 30 & 3.9\% & 0.06 [0.05, 1.12] \\ \text{Subtatal (95% Cl)} & 1.83 & 0.48 & 30 & 1.79 & 0.71 & 30 & 3.9\% & 0.06 [0.05, 1.02] \\ \text{Subtatal (95% Cl)} & 1.83 & 0.48 & 30 & 1.79 & 0.71 & 30 & 3.9\% & 0.06 [0.05, 1.02] \\ \text{Subtatal (95% Cl)} & 1.83 & 0.48 & 30 & 1.79 & 0.71 & 30 & 3.9\% & 0.06 [0.05, 0.05] \\ \text{Subtatal effect Z = 1.92 (P = 0.07) \\ \textbf{3.16 Menutal effect Z = 1.92 (P = 0.07) \\ \textbf{3.16 Menutal effect Z = 2.48 & 0.228 & 0.68 & 100 & 0.2\% & 0.31 [0.02, 0.5] \\ \text{Heterogeneity: Tayle = 0.03; Chir = 11.08, dir = 3 (P = 0.01); P = 73\% \\ \text{Test for overall effect Z = 2.48 & 0.43 & 10.6 & 5.3\% & 0.44 [0.19, 0.63] \\ \text{Shi 2021 } & 3.64 & 0.43 & 0.39 & 3.2\% & 0.44 [0.19, 0.63] \\ Heterogeneity: Tayle = 0.03; Chir = 10.08 & 30 & 2.30 & 0.49 & 30 & 2.7\% & 0.01 [0.26, 0.56] \\ \text{Heterogeneity: Tayle = 0.03; Chir = 0.023; P = 0.23; P = 3.2\% \\ \text{Test for overall effect Z = 2.515 (P = 0.000001); P = 75\% \\ \text{Test for overall effect Z = 2.515 (P = 0.000001); P = 75\% \\ \text{Test for overall effect Z = 2.515 (P = 0.000001); $	Shi 2021	5.22 0.49	100	4.86	0.25	100	6.9%	0.36 [0.25, 0.47]	
Subtratia (95% CI) 196 116.8, df = 3 (P = 0.006); P = 74% Testfor overall effect $Z = 3.48$ (P = 0.0005) 3.1.3 Usuespatial dystunction/Kxecuthes function Ran 2020 3.88 1.46 36 3.15 1.52 36 1.4% Shi 2021 3.91 1.44 100 3.11 1.49 100 3.09% 0.68 (0.03, 1.21] Shi 2021 4.17 1.31 30 3.31 1.49 100 3.09% 0.68 (0.07, 1.01] Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.39, df = 3 (P = 0.71); P = 0% Testfor overall effect $Z = 5.76$ (P = 0.00001) 3.1.4 Abstract ability Ran 2020 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 (0.06, 1.12] Shi 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.68 (0.34, 0.98] Wang 2020 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 (0.06, 1.12] Shi 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.68 (0.34, 0.98] Wang 2020 4.73 1.12 36 4.14 3.00 Subtrait (95% CI) 196 14.8% 0.31 [-0.02, 0.65] Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.2.11, df = 3 (P = 0.07); P = 75% Testfor overall effect $Z = -5.70$ (S $-36 - 2.14 - 0.6 36 4.6% 0.43 (0.16, 0.70]$ Shi 2021 2.73 0.65 36 2.14 0.6 36 4.03 0.32 (0.44 [0.53, 0.25] Wang 2020 2.67 0.65 36 2.14 0.6 36 4.6% 0.43 (0.16, 0.70] Shi 2021 2.73 0.69 100 2.26 0.55 100 6.2% 0.47 (0.31, 0.63] Wang 2020 2.67 0.65 36 2.14 0.6 36 4.6% 0.43 (0.16, 0.70] Shi 2021 2.73 0.69 100 2.26 0.55 100 6.2% 0.47 (0.31, 0.63] Wang 2020 2.67 0.65 36 2.14 0.6 36 4.6% 0.43 (0.16, 0.70] Shi 2021 2.73 0.69 100 2.26 0.55 100 6.2% 0.47 (0.31, 0.63] Wang 2021 2.63 0.64 3.03 0.43 100 6.8% 0.43 (0.16, 0.70] Heterogeneity: Tau <sup>2</sup> = 0.03; Ch <sup>2</sup> = 1.10.8, df = 3 (P = 0.01); P = 73% Testfor overall effect $Z = 2.48 (P = 0.01)$ Heterogeneity: Tau <sup>2</sup> = 0.03; Ch <sup>2</sup> = 1.10.8, df = 3 (P = 0.22); P = 32% Testfor overall effect $Z = 2.43 0.65 3.06 3.03 0.43 100 6.63% 0.44 (0.15, 0.65] Heterogeneity: Tau2 = 0.03; Ch2 = 4.44, df = 3 (P = 0.22); P = 32% Testfor overall effect Z = 8.15 (P = 0.00001)Heterogeneity: Tau2 = 0.03; Ch2 = 0.030; P = 0.22; P = 32%Testfor overall effect Z = 8.57 (P = 0.000001); P = 75%Testfor overall effect Z = 8.57 (P = 0.000001); P = 75%Testfor overall effect Z = 8.57 (P = $	VVang 2021	5.94 1.37	. 30	4.18	1.93	30	1.0%	1.76 [0.91, 2.61]	
Subtratia (95% CI) 196 116.8, df = 3 (P = 0.006); P = 74% Testfor overall effect $Z = 3.48$ (P = 0.0005) 3.1.3 Usuespatial dystunction/Kxecuthes function Ran 2020 3.88 1.46 36 3.15 1.52 36 1.4% Shi 2021 3.91 1.44 100 3.11 1.49 100 3.09% 0.68 (0.03, 1.21] Shi 2021 4.17 1.31 30 3.31 1.49 100 3.09% 0.68 (0.07, 1.01] Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.39, df = 3 (P = 0.71); P = 0% Testfor overall effect $Z = 5.76$ (P = 0.00001) 3.1.4 Abstract ability Ran 2020 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 (0.06, 1.12] Shi 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.68 (0.34, 0.98] Wang 2020 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 (0.06, 1.12] Shi 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.68 (0.34, 0.98] Wang 2020 4.73 1.12 36 4.14 3.00 Subtrait (95% CI) 196 14.8% 0.31 [-0.02, 0.65] Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.2.11, df = 3 (P = 0.07); P = 75% Testfor overall effect $Z = -5.70$ (S $-36 - 2.14 - 0.6 36 4.6% 0.43 (0.16, 0.70]$ Shi 2021 2.73 0.65 36 2.14 0.6 36 4.03 0.32 (0.44 [0.53, 0.25] Wang 2020 2.67 0.65 36 2.14 0.6 36 4.6% 0.43 (0.16, 0.70] Shi 2021 2.73 0.69 100 2.26 0.55 100 6.2% 0.47 (0.31, 0.63] Wang 2020 2.67 0.65 36 2.14 0.6 36 4.6% 0.43 (0.16, 0.70] Shi 2021 2.73 0.69 100 2.26 0.55 100 6.2% 0.47 (0.31, 0.63] Wang 2020 2.67 0.65 36 2.14 0.6 36 4.6% 0.43 (0.16, 0.70] Shi 2021 2.73 0.69 100 2.26 0.55 100 6.2% 0.47 (0.31, 0.63] Wang 2021 2.63 0.64 3.03 0.43 100 6.8% 0.43 (0.16, 0.70] Heterogeneity: Tau <sup>2</sup> = 0.03; Ch <sup>2</sup> = 1.10.8, df = 3 (P = 0.01); P = 73% Testfor overall effect $Z = 2.48 (P = 0.01)$ Heterogeneity: Tau <sup>2</sup> = 0.03; Ch <sup>2</sup> = 1.10.8, df = 3 (P = 0.22); P = 32% Testfor overall effect $Z = 2.43 0.65 3.06 3.03 0.43 100 6.63% 0.44 (0.15, 0.65] Heterogeneity: Tau2 = 0.03; Ch2 = 4.44, df = 3 (P = 0.22); P = 32% Testfor overall effect Z = 8.15 (P = 0.00001)Heterogeneity: Tau2 = 0.03; Ch2 = 0.030; P = 0.22; P = 32%Testfor overall effect Z = 8.57 (P = 0.000001); P = 75%Testfor overall effect Z = 8.57 (P = 0.000001); P = 75%Testfor overall effect Z = 8.57 (P = $		5.63 0.67	30	5.17	0.87	30	3.1%		
Test for overall effect: $Z = 5.48 \ (P = 0.0005)$ 3.13 Official destinct clone function Shi 2021 3.89 1.46 36 3.15 1.52 36 1.4% 0.73 [0.04, 1.42] Shi 2021 3.89 1.44 100 3.11 1.49 100 3.01% 0.80 [0.39, 1.21] Wang 2021 4.19 1.31 30 3.17 1.48 30 1.3% 1.02 [0.31, 1.73] Thest for overall effect $Z = 5.57 \ (P = 0.00001)$ 3.14 Abstract ability Ran 2020 Shi 2021 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 [0.06, 1.12] Shi 2021 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 [0.06, 1.12] Shi 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.68 [0.34, 0.39] Zhang 2020 Coverall effect $Z = 5.57 \ (P = 0.00001)$ 3.15 Abstract ability Ran 2020 Test for overall effect $Z = 5.57 \ (P = 0.0007); P = 75\%$ Test for overall effect $Z = 5.77 \ (P = 0.0007); P = 75\%$ Test for overall effect $Z = 1.82 \ (P = 0.07); P = 75\%$ Test for overall effect $Z = 1.82 \ (P = 0.07); P = 75\%$ Test for overall effect $Z = 1.82 \ (P = 0.07); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.515 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 2.515 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 2.517 \ (P = 3.000001); P = 72\%$ Test for overall effect $Z = 8.17 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 8.17 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 8.17 \ (P = 0.00001); P = 7$			196			196	16.7%		
Test for overall effect: $Z = 5.48 \ (P = 0.0005)$ 3.13 Official destinct clone function Shi 2021 3.89 1.46 36 3.15 1.52 36 1.4% 0.73 [0.04, 1.42] Shi 2021 3.89 1.44 100 3.11 1.49 100 3.01% 0.80 [0.39, 1.21] Wang 2021 4.19 1.31 30 3.17 1.48 30 1.3% 1.02 [0.31, 1.73] Thest for overall effect $Z = 5.57 \ (P = 0.00001)$ 3.14 Abstract ability Ran 2020 Shi 2021 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 [0.06, 1.12] Shi 2021 4.73 1.12 36 4.14 1.17 36 2.1% 0.59 [0.06, 1.12] Shi 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.68 [0.34, 0.39] Zhang 2020 Coverall effect $Z = 5.57 \ (P = 0.00001)$ 3.15 Abstract ability Ran 2020 Test for overall effect $Z = 5.57 \ (P = 0.0007); P = 75\%$ Test for overall effect $Z = 5.77 \ (P = 0.0007); P = 75\%$ Test for overall effect $Z = 1.82 \ (P = 0.07); P = 75\%$ Test for overall effect $Z = 1.82 \ (P = 0.07); P = 75\%$ Test for overall effect $Z = 1.82 \ (P = 0.07); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.48 \ (P = 0.01); P = 75\%$ Test for overall effect $Z = 2.515 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 2.515 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 2.517 \ (P = 3.000001); P = 72\%$ Test for overall effect $Z = 8.17 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 8.17 \ (P = 0.00001); P = 72\%$ Test for overall effect $Z = 8.17 \ (P = 0.00001); P = 7$	Heterogeneity: Tau <sup>2</sup>	= 0.04; Chi <sup>2</sup> = '	11.58. df	= 3 (P = 1)	0.009	$1^2 = 7$	4 %		
Ran 2020       3.88       1.46       36       3.15       1.52       36       1.4%       0.72 [0.04, 1.42]         Shi 2021       3.91       1.44       100       3.11       1.49       100       3.0%       0.80 [0.38, 1.21]         Wang 2021       4.19       1.31       30       3.17       1.48       30       1.3%       1.02 [0.31, 1.73]         Jhang 2026       G.0       Ch <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.36, df = 3 (P = 0.71); P = 0%       0.54 [0.07, 1.01]       0.54 [0.07, 1.01]         Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.36, df = 3 (P = 0.71); P = 0%       0.55 [0.06, 1.12]       0.58 [0.06, 1.03]         Sta 2020       4.72       1.23       30       1.77       0.43       30       5.5%       0.04 [0.31, 0.36]         Wang 2021       1.83       0.46       30       1.77       0.43       30       5.2%       0.06 [0.07, 0.26]         Subtotal (95% Ch)       196       14.8%       0.43 [0.16, 0.70]       0.31 [0.63]       0.31 [0.02, 0.63]         Wang 2021       2.03       0.24 [0.05, 36       0.47 [0.31, 0.63]       0.47 [0.31, 0.63]       0.47 [0.31, 0.63]         Wang 2021       2.03       0.24 [0.01); P = 73%       0.41 [0.02, 0.63]       0.42 [0.66, 0.50]       0.41 [0.3, 0.63]       0.41 [0.3, 0.63]					0.000	/.·-·	4.70		
Shi 2021 3.91 1.44 100 3.11 1.48 100 3.0% 0.80 $[0.36, 1.21]$ Wang 2021 4.37 0.81 30 3.17 1.48 30 1.3% 1.02 0.03, 1.73] Zhang 2020 $(-1)^{14}$ 1.39 $(-3)^{14}$ 1.30 $(-3)^{14}$ 1.30 $(-3)^{14}$ 1.30 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.21 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{14}$ 1.20 $(-3)^{1$						-		0.70.004.4.40	
Wang 2021       4.19       1.31       30       3.17       1.48       30       1.3%       1.02 [0.31, 1.73]         Subtotal (95% CI)       130       3.83       1.02       0.25 (%)       0.54 [0.07, 1.01]         Heterogenelity: Tau" = 0.00; ChiP = 1.33, df = 3 (P = 0.71); P = 0%       156       8.3%       0.74 [0.48, 1.00]         Subtotal (95% CI)       4.73       1.12       36       4.14       1.17       36       2.1%       0.59 [0.06, 1.12]         Shi 2020       4.73       1.12       36       4.14       1.17       36       0.59 [0.06, 1.12]         Shi 2021       4.73       1.63       0.48       300       1.77       0.73       30       6.2%       0.06 [0.31, 0.29]         Subtotal (95% CI)       1.63       0.68       30       1.77       0.73       30       6.2%       0.041 [0.15, 0.70]         Subtotal (95% CI)       1.63       0.69       1.06       0.41 [0.31, 0.63]       0.28 [0.06, 0.50]         Subtotal (95%; CI)       2.73       0.55       100       6.2%       0.43 [0.16, 0.70]         Shi 2021       2.73       0.56       30       2.73       0.45       30       5.2%         Vang 2020       2.65       30       2.73 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$									
Subtidial (95% CI)       196       196       196       8.3%       0.74 [0.48, 1.00]         Heterogenelity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.39, df = 3 (P = 0.71); P = 0%       Test for overall effect Z = 1.57 (P < 0.00001)									
Histerogeneity: $Tau^{\mu} = 0.00; Ch^{\mu} = 1.39, dr = 3 (P = 0.71); P = 0\%$ Test for overall effect $Z = 5.57 (P < 0.00001)$ 3.1.4 Abstract ability Ran 2020 4.72 1.23 100 4.06 1.05 100 3.9% 0.68 [0.34, 0.98] Wang 2021 4.73 0.47 1.72 1.9 5 4.14 1.17 36 2.1% 0.68 [0.34, 0.98] Wang 2021 1.83 0.48 30 1.77 0.43 30 5.2% 0.04 [-0.31, 0.39] Heterogeneity: Tau^{\mu} = 0.09; ChP = 12.11, dr = 3 (P = 0.007); P = 75%. Test for overall effect $Z = 1.22 (P = 0.07)$ 3.1.5 Naming ability Ran 2020 2.67 0.55 36 2.14 0.6 36 4.6% 0.43 [0.16, 0.70] Shi 2021 2.73 0.59 100 2.26 0.55 100 6.2% 0.47 [0.31, 0.63] Wang 2021 2.33 0.25 30 2.73 0.45 30 5.8% 0.20 [0.02, 0.38] Defensive the start of the star		4.37 0.81		3.83	1.02				
Test for overall effect $Z = 2.57$ (P = 0.00001) 3.1-4 Abstract ability Fan 2020 Shi 2021 4.72 1.12 36 4.14 1.17 36 2.1% 0.59 [0.05, 1.12] Shi 2021 4.72 1.23 100 4.06 1.05 100 3.9% 0.66 [0.34, 0.98] Wang 2021 1.83 0.86 30 1.77 0.43 30 5.2% 0.006 [0.017, 0.29] Heat openets Tuf#= 0.09; Ch#=12.19 7.15 Naming ability Ran 2020 2.65 30 2.24 0.65 100 6.2% 0.04 [-0.31, 0.63] Subtotal (95% Cl) 196 11.08, df = 3 (P = 0.01); P = 75% Test for overall effect $Z = 2.48$ (P = 0.01) 3.16 Linguistic competence Ran 2020 3.64 0.43 36 3.13 0.52 36 5.3% 0.41 [0.19, 0.63] Subtotal (95% Cl) 196 196 0.20 2.27 0.65 100 6.2% 0.41 [0.19, 0.63] Subtotal (95% Cl) 196 196 0.23 0.23 0.27 30.45 30 0.27 % Test for overall effect $Z = 5.15$ (P = 0.00) Test for overall effect $Z = 5.15$ (P = 0.0001) Total (95% Cl) 1176 100.09 Heterogeneity: Tau <sup>2</sup> = 0.01; ChP = 4.24 (Af = 3 (P = 0.21); P = 73% Test for overall effect $Z = 5.15$ (P = 0.0001) Total (95% Cl) 1176 196 19.5% 0.41 [0.19, 0.63] Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.24 (Af = 3 (P = 0.22); P = 32% Test for overall effect $Z = 5.15$ (P = 0.00001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.24 (Af = 3 (P = 0.02); P = 75% Test for overall effect $Z = 5.15$ (P = 0.00001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.24 (Af = 3 (P = 0.02); P = 75% Test for overall effect $Z = 7.77$ (P = 0.000001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.24 (Af = 3 (P = 0.02); P = 75% Test for overall effect $Z = 7.77$ (P = 0.000001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.24 (P = 2.000001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.44 (H = 3 (P = 0.02); P = 75% Test for overall effect $Z = 8.15$ (P = 0.00001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.24 (P = 2.00001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.24 (P = 3.20) (P = 0.00001); P = 75% Test for overall effect $Z = 8.77$ (P = 0.00001) Heterogeneity: Tau <sup>2</sup> = 0.03; ChP = 4.44 (H = 3 (P = 0.00001); P = 75% Test for overall effect $Z = 8.77$ (P = 0.00001)							8.3%	0.74 [0.48, 1.00]	
Ran 2020       4.72       1.12       36       4.14       1.17       36       2.1%       0.55       10.06       1.12]         Shi 2021       4.72       1.23       100       4.06       1.05       100       3.9%       0.65       10.34       0.39]         Wang 2021       1.83       0.88       30       1.79       0.71       30       3.6%       0.04 [-0.31, 0.39]         Yang 2025%       1       1.83       0.48       30       1.79       0.71       30       5.2%       0.04 [-0.31, 0.39]         Heterogeneity: Tau*= 0.09; Chi*= 12.11, dr = 3 (P = 0.007); P = 75%.       0.31 [-0.02, 0.65]       0.31 [-0.02, 0.65]       0.31 [-0.02, 0.65]         State 2021       2.73       0.59       100       2.26       0.55       100       6.2%       0.47 [0.31, 0.63]         Wang 2021       2.03       0.25       30       2.73       0.45       30       5.8%       0.20 [0.02, 0.38]         Subtotal (95% CI)       1166       19.6       19.6%       0.41 [0.19, 0.63]					0.71); P	= 0%			
Shi 2021       4.72       1.23       100       4.06       1.06       100       3.9%       0.66       0.34       0.98         Vwang 2021       1.83       0.46       30       1.77       0.43       30       5.2%       0.06       0.04       0.31       0.39         Subtotal (95% CI)       1.83       0.46       30       1.77       0.43       30       5.2%       0.06       1.01       0.29         Subtotal (95% CI)       1.83       0.46       30       1.77       0.43       30       5.2%       0.06       1.01       0.23         Hetrogenetic: Tau"=0.09; Ch"= 12.1, df" = 3 (P = 0.007); P = 75%       Test for overall effect Z = 1.82 (P = 0.07)	3.1.4 Abstract abilit	У							
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Ran 2020	4.73 1.12	36			36		0.59 [0.06, 1.12]	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Shi 2021	4.72 1.23	100	4.06	1.05	100	3.9%	0.66 [0.34, 0.98]	
Subtotal (95% CI)       196       196       14.8%       0.31 [-0.02, 0.65]         Heterogenelity: Tau# = 0.09; Ch# = 12:11, df = 3 (P = 0.007); P = 75%       0.31 [-0.02, 0.65] <ul> <li>Test for overall effect Z = 1.82 (P = 0.07)</li> <li>The strong ability</li> <li>Sha 2020</li> <li>Sin 2021</li> <li>2.75</li> <li>0.59</li> <li>100</li> <li>2.65</li> <li>100</li> <li>2.75</li> <li>0.59</li> <li>100</li> <li>2.65</li> <li>106</li> <li>106</li> <li>106</li> <li>106</li> <li>106</li> <li>106</li> <li>0.51</li> <li>0.28 [0.06, 0.50]</li> <li>0.28 [0.03, 0.61]</li> <li>100</li> <li>0.43</li> <li>0.52</li> <li>0.41 [0.19, 0.63]</li> <li>0.41 [0.19, 0.63]</li> <li>100</li> <li>1.96</li> <li>0.42</li> <li>0.52</li> <li>0.41 [0.28, 0.55]</li> <li>0.41 [0.28, 0.55]</li> <li>0.41 [0.28, 0.55]</li> <li>0.41 [0.28</li></ul>	Wang 2021	1.83 0.66	30	1.79	0.71	30	3.5%	0.04 (-0.31, 0.39)	
Heterogeneity: $Tau^{\mu} = 0.09$ ; $Chl^{\mu} = 12.11$ , $dr = 3$ ( $P = 0.007$ ); $P = 75\%$ Test for overall effect $Z = 1.22$ ( $P = 0.07$ ) 3.15 Naming ability Ran 2020 2.57 0.55 36 2.14 0.6 36 4.6% 0.43 [0.16, 0.70] Shi 2021 2.73 0.59 100 2.26 0.55 100 6.2% 0.47 [0.31, 0.63] Zhang 2021 2.03 0.69 30 2.17 0.84 30 3.2% 0.44 [0.53, 0.25] Zhang 2020 2.03 0.25 30 2.73 0.45 30 5.8% 0.20 [0.02, 0.38] District (95% CI) 4.41 100 302 0.43 100 6.8% 0.41 [0.19, 0.63] Shi 2021 3.52 0.41 100 302 0.43 100 6.8% 0.40 [0.37, 0.51] Zhang 2020 3.54 0.43 36 3.13 0.52 38 6.3% 0.41 [0.19, 0.63] Shi 2021 3.52 0.41 100 302 0.43 100 6.8% 0.40 [0.37, 0.51] Zhang 2020 3.54 0.43 ( $P = 0.01$ ); $P = 73\%$ Test for overall effect $Z = 1.5$ ( $P < 0.00001$ ) Heterogeneity: $Tau^{\mu} = 0.01$ ; $Chl^{\mu} = 4.44$ , $dr = 3$ ( $P = 0.22$ ); $P = 32\%$ Test for overall effect $Z = 5.15$ ( $P < 0.00001$ ) Heterogeneity: $Tau^{\mu} = 0.03$ ; $Chl^{\mu} = 490.2$ , $dr = 23$ ( $P < 0.00001$ ); $P = 75\%$ Test for overall effect $Z = 5.7$ ( $P < 0.00001$ )	Zhang 2020	1.83 0.46	; 30	1.77	0.43	30	5.2%	0.06 (-0.17, 0.29)	
Test for overall effect: Z = 1.82 (P = 0.07)         3.1.5 Naming ability         Ran 2020       2.57       0.55         98 and 2021       2.57       0.55         100 226       0.55       100       2.26         101 220       2.57       0.59       100       2.26         111 2020       2.03       0.69       100       2.26       0.55         111 2020       2.03       0.69       100       2.26       0.55       100       0.28         2020       2.03       0.29       196       196       196       0.28       0.020       0.29         Subtotal (95% CI)       196       196       196       0.28       0.020       0.89         14eterogeneity: Tau" = 0.03; Chl" = 11.08, dr = 3 (P = 0.01); l" = 73%       0.43       0.62       3.64       0.41       0.93       0.41         Shi 2021       3.62       0.41       0.3       0.63       0.41       0.44       0.43       0.41       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44	Subtotal (95% CI)		196			196	14.8%	0.31 [ 0.02, 0.65]	
Test for overall effect: Z = 1.82 (P = 0.07)         3.1.5 Naming ability         Ran 2020       2.57       0.55         98 and 2021       2.57       0.55         100 226       0.55       100       2.26         101 220       2.57       0.59       100       2.26         111 2020       2.03       0.69       100       2.26       0.55         111 2020       2.03       0.69       100       2.26       0.55       100       0.28         2020       2.03       0.29       196       196       196       0.28       0.020       0.29         Subtotal (95% CI)       196       196       196       0.28       0.020       0.89         14eterogeneity: Tau" = 0.03; Chl" = 11.08, dr = 3 (P = 0.01); l" = 73%       0.43       0.62       3.64       0.41       0.93       0.41         Shi 2021       3.62       0.41       0.3       0.63       0.41       0.44       0.43       0.41       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44       0.44		= 0.09° Chi* = 1	2.11 df	= 3 (P =	0.007	1 = 7			_
Ran 2020       2.57       0.56       36       2.14       0.6       36       4.6%       0.43 [0.16, 0.70]         Shi 2021       2.73       0.59       100       2.26       0.55       100       6.2%       0.47 [0.31, 0.63]         Wang 2021       2.03       0.69       30       2.17       0.84       30       3.2%       -0.14 [-0.53, 0.25]         Subtotal (95% CI)       196       73       0.45       30       5.8%       0.22 [0.02, 0.38]         Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11.08, drf = 3 (P = 0.01); P = 73%									
Shi 2021       2.73       0.59       100       2.26       0.55       100       6.2%       0.47 [0.31, 0.63]         Wang 2021       2.03       0.89       30       2.17       0.84       30       3.2%       0.14 [0.53, 0.25]         Zhang 2020       2.03       0.25       30       2.73       0.45       30       5.8%       0.20 [0.02, 0.38]         Stabtoal (selby, Tau" = 0.03; Ch" = 11.08 df = 3 (P = 0.01); P = 73%       73       0.45       30       5.8%       0.20 [0.02, 0.38]         Test for overall effect: Z = 2.48 (P = 0.01)       31.3       0.52       36       5.3%       0.41 [0.19, 0.63]         Shiptotal (95% CI)       3.654       0.43       30       3.052       36       0.43       0.01 [0.02, 0.63]         Shiptotal (95% CI)       3.62       0.44       100       30.64       0.43       0.63       0.41 [0.19, 0.63]         Shiptotal (95% CI)       1.96       196       196       0.5%       0.01 [-0.4, 0.64]									
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$									
Zhang 2020       2.93       0.26       30       2.73       0.46       30       6.8%       0.20 [0.02, 0.38]         Subtotal (95% CI)       11       0.6, df = 1       196       19.8%       0.28 [0.06, 0.50]         Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 11:08, df = 3 (P = 0.01); I <sup>2</sup> = 73%       5.8%       0.41 [0.19, 0.63]									
Subtotal (95% Cl)       196       196       196       19.8%       0.28 [0.06, 0.50]         Heterogeneity: Tau" = 0.03; Chi" = 11.08, drf = 3 (P = 0.01); i" = 73%       0.28 [0.06, 0.50] <ul> <li>Test for overall effect: Z = 2.48 (P = 0.01); i" = 73%</li> <li>Test for overall effect: Z = 2.48 (P = 0.01); i" = 73%</li> <li>Shi 2020</li> <li>3.64</li> <li>0.43</li> <li>3.6 1.100</li> <li>3.64</li> <li>0.43</li> <li>3.6 3.13</li> <li>0.52</li> <li>3.6 5.3%</li> <li>0.41 [0.19, 0.63]</li> <li>Test for overall effect: Z = 8.15 (P &lt; 0.00001)</li> <li>Heterogeneity: Tau" = 0.03; Chi" = 90.92; drf = 23 (P &lt; 0.00001); i" = 75%</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001)</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001); i" = 75%</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001)</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001); i" = 75%</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001); i" = 75%</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001); i" = 75%</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001); i" = 75%</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001); i" = 75%</li> <li>Test for overall effect: Z = 8.77 (P &lt; 0.00001); in a point po</li></ul>									
Heterogeneity: $Tau^a = 0.03$ ; $Chl^a = 11.08$ , $dr = 3$ ( $P = 0.01$ ); $l^a = 73\%$ Test for overall effect: $Z = 2.48$ ( $P = 0.01$ ) <b>3.1.6 Linguistic competence</b> Ran 2020       3.64       0.43       36       5.3%       0.41 [0.19, 0.63]         Shi 2021       3.52       0.41       1.09       0.68%       0.49 [0.37, 0.61]         Wang 2021       1.99       0.94       30       1.98       0.82       30       2.7%       0.01 [-0.44, 0.46]         Sharadi (25% CI)       2.43       0.5       30       0.49 [0.37, 0.61]		2.93 0.25		2.73	0.45				
Test for overall effect. Z = 2.48 (P = 0.01)         3.1.6 Linguistic completence         Bin 2020       3.62       4.3       36       3.1.5       2.6       5.3%       0.41 [0.19, 0.63]         Bin 2021       3.62       0.43       3.0       0.43       100       5.0%       0.49 [0.37, 0.63]         Wang 2021       1.99       0.94       30       1.98       0.82       30       2.7%       0.01 [-0.44, 0.46]         Subtotal (95% Cl)       196       196       196, 19.5%       0.41 [0.28, 0.55]	Subtotal (95% CI)		196			196	19.8%	0.28 [0.06, 0.50]	-
Ran 2020       3.64       0.43       36       3.13       0.52       36       0.41       [0.16, 0.63]         Shi 2021       3.62       0.41       100       3.03       0.43       100       6.8%       0.44       [0.37, 0.61]         Wang 2021       1.99       0.94       30       1.98       0.82       30       2.7%       0.01       [0.44, 0.46]         Subtotal (95% CI)       196       196       196       196       0.41       [0.28, 0.55]         Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 4.04, df = 3 (P = 0.22); P = 32%       0.41       [0.31, 0.50]				'= 3 (P =	0.01);	I <sup>e</sup> = 73	196		
Shi 2021       3.52       0.41       100       3.03       0.43       100       6.8%       0.49 [0.37, 0.61]         Wang 2021       1.99       0.94       0.198       0.22       30       2.7%       0.01 [-0.44, 0.46]         Zhang 2020       2.43       0.5       30       2.03       0.49       30       4.8%       0.040 [0.15, 0.65]         Subtotal (95% CI)       196       196       19.5%       0.41 [0.28, 0.55]       •         Heterogeneity: Tau² = 0.01; Chi² = 4.44, df = 3 (P = 0.22); I² = 32%       •       •       •         Test for overall effect: Z = 8.71 (P < 0.00001)	3.1.6 Linguistic com	petence							
Shi 2021       3.52       0.41       100       3.03       0.43       100       6.8%       0.49 [0.37, 0.61]         Wang 2021       1.99       0.94       0.198       0.22       30       2.7%       0.01 [-0.44, 0.46]         Zhang 2020       2.43       0.5       30       2.03       0.49       30       4.8%       0.040 [0.15, 0.65]         Subtotal (95% CI)       196       196       19.5%       0.41 [0.28, 0.55]       •         Heterogeneity: Tau² = 0.01; Chi² = 4.44, df = 3 (P = 0.22); I² = 32%       •       •       •         Test for overall effect: Z = 8.71 (P < 0.00001)	Ran 2020	3.54 0.43	36	3.13	0.52	36	5.3%	0.41 [0.19, 0.63]	
Wang 2021       1.99       0.94       30       1.98       0.82       30       2.7%       0.01 [-0.44] (0.46]         Zhang 2020       2.43       0.5       30       2.03       0.49       30       4.8%       0.40 [0.15] (0.65]         Subtotal (95% Cl)       196       196       196       19.5%       0.41 [0.26, 0.55]         Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 4.44, df = 3 (P = 0.22); I <sup>2</sup> = 32%       0.41 [0.31, 0.50]       •         Totat (95% Cl)       1176       1176       100.0%       0.41 [0.31, 0.50]         Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 90.92, df = 23 (P < 0.00001); I <sup>2</sup> = 75%       0.41 [0.31, 0.50]       •         Test for overail effect: Z = 8.77 (P < 0.00001)									
Zhang 2020       2.43       0.5       30       2.03       0.49       30       4.8%       0.40 [0.15, 0.65]         Subtotal (95% CI)       196       196       19.5%       0.41 [0.28, 0.55]         Heterogeneity: Tau² = 0.01; Chi² = 4.44, df = 3 (P = 0.22); I² = 32%       0.41 [0.28, 0.55]       •         Total (95% CI)       1176       100.0%       0.41 [0.31, 0.50]       •         Heterogeneity: Tau² = 0.03; Chi² = 90.92, df = 23 (P < 0.00001); I² = 75%									
Subtrivial (95% Cl)         196         196         196         195%         0.41 [0.28, 0.55]           Heterogeneity: Tau" = 0.01; Chi" = 4.44, df = 3 (P = 0.22); I" = 32%         Test for overall effect: Z = 8.15 (P < 0.00001)									
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 4.44, df = 3 (P = 0.22); i <sup>2</sup> = 32% Test for overall effect: Z = 6.15 (P < 0.00001) Total (95% Cl) = 1176 1176 100.0% Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 90.92, df = 23 (P < 0.00001); i <sup>2</sup> = 75% Test for overall effect: Z = 8.77 (P < 0.00001) Factor overall effect: Z = 8.77 (P < 0.00001)		2.1.5 0.0		2.00	0.70				•
Heterogeneity: Tau*= 0.03; Chi*= 90.92, df = 23 (P < 0.00001); i*= 75%	Heterogeneity: Tau <sup>2</sup>		4.44, df=		0.22); P				
Heterogeneity: Tau*= 0.03; Chi*= 90.92, df = 23 (P < 0.00001); i*= 75%									
Test for overall effect: Z = 8.77 (P < 0.00001) - 2 Eavours [experimental] Eavours [control]								0.41 [0.31, 0.50]	
Test for overall effect: Z = 8.77 (P < 0.00001) Eavours [experimental] Eavours [control]					< 0.00	001); P	= 75%	-	
Test for subaroup differences: Chi#= 8.01. df = 5 (P = 0.16). I#= 37.6%									
	Test for subaroup di	ifferences: Chi <sup>a</sup>	= 8.01.	df = 5 (P	= 0.16	5). I* = 3	37.6%		r arears texperimental, i avoura teoritroit

Figure 3. Forest plot of MoCA

## **3.5.** Activities of Daily Living(ADL)

BI are widely used basic ADL measures with good reliability and validity, and can quantify functional changes after stroke rehabilitation [9,10]. 7 studies used BI involving 638 patients, meta-analysis showed WMD=7.43, 95% CI:6.21 to 8.66, P<0.05,  $I^2=67\%$ . Sensitivity analysis was used to eliminate articles one by one, and it was found that the Xing study was the main cause of heterogeneity, which may be related to the short course of the included patients and the high risk of bias.

## **3.6. Auditory Event-related Potential (P300)**

P300 is a mature and objective neurophysiological method, which is widely used in the assessment of cognitive function in patients with nervous system. The more severe the cognitive injury, the longer the latency, and the smaller the amplitude. A total of 3 studies documented changes in P300 latency and amplitude before and after treatment.Meta-analysis revealed that the latency (WMD=-13.75,95%CI:-24.91to -2.59,P<0.05 , I<sup>2</sup>= 88%) and the amplitude (WMD = 0.91, 95% CI: 0.42 to 1.39, P<0.05,I<sup>2</sup>=53%) significantly differed between the acupuncture + cognitive training and control groups. These results indicated that acupuncture + cognitive training could effectively improve global cognition in patients with PSCI.

## **3.7. Publication Bias**

The funnel plot of MoCA showed that most of the scattered points were in the middle and upper part, indicating that publication bias was small.And the Egger test on MoCA( P=0.72), which also confirmed the small possibility of bias(Figure 4).




Figure 4. The funnel plot of MoCA

## 4. Discussion

Western medicine believes that the pathogenesis of PSCI may be related to direct damage of cognitive brain structures, neuroinflammation and cytotoxicity, damage of default and central executive network, and damage of cholinergic transmitter system [11,12]. At present, the western medicine treatment of PSCI includes medicine, physical therapy, cognitive rehabilitation training and so on. The overall efficacy of drug and physical therapy is average, and there are problems such

as unclear treatment mechanism, poor safety, and high cost [13]. As a green and safe intervention, cognitive training is deeply loved by people. According to the cognitive rehabilitation theory, after a certain intense and repeated sensory stimulation and functional training, the surrounding normal brain tissue can compensate the damaged brain tissue, thereby promoting the rehabilitation of cognitive function in PSCI patients [14]. Traditional Chinese medicine believes that the occurrence of PSCI is related to the damage of brain collaterals after stroke, obstruction of meridians, loss of nourishing, and dysfunction of inherent spirit. The disease location is in the brain, and the disease character is virtual real, real isblood stasis and phlegm [15]. Acupuncture is the most common with obvious advantages in improving intelligence, stimulating consciousness and therapy enhancing memory and other cognitive fields. Modern studies have found that acupuncture can improve cognitive impairment after stroke by regulating signaling pathways [16], affecting the expression of related proteins [17], restoring vascular endothelial function [18,19], and increasing the functional connectivity of brain network [20]. Numerous studies [21-23] have shown that acupuncture combined with cognitive training has the best efficacy compared with acupuncture alone.

The results showed that the combined group was superior to the single treatment group in improving the total effective rate, increasing the score of MoCA, BI, and P300 amplitude, and reducing the delay of P300. And indicated that acupuncture combined with cognitive training had certain advantages over the single therapy in PSCI treatment, and also indicated that acupuncture and cognitive training were synergistic. Acupuncture and cognitive training may affect brain plasticity through different and complementary pathways, that is, acupuncture induces physiological changes ( up-regulation of brain-derived neurotrophic factor and stimulation of hippocampal neurogenesis), and in turn, promotes neuroplastic effects after cognitive training, thereby producing therapeutic effects on functional impairment in neurological diseases. But, some of the included studies exist interference factors. In terms of stroke type, all 12 studies involved ischemic stroke patients; 15 studies included patients with bleeding and ischemic stroke, and 3 studies included only post-stroke patients. In addition, there were differences in basic treatment, rehabilitation programs, education level and stroke period among different studies. However, the funnel plots of effective rate existence of publication bias, indicating that the objectivity of the data needs further discussion.

Our systematic review has the following limitations: (1) Although random allocation method was mentioned in all the included studies, the implementation process was not specifically described, and most of the studies did not implement allocation hiding and blind method1, which had a high risk of bias; (2) Insufficient sample size and lack of sample size estimation in the included study reduced the reliability of the conclusions of this study to some extent; (3) Many studies cannot be combined and analyzed due to differences in the degree of cognitive impairment, intervention programs and efficacy evaluation criteria included in the studies; (4) Acupuncture frequency, acupuncture depth, stimulation site, number of acupuncture points and basic treatment were different in different studies, and there was great clinical heterogeneity. (5)There is a lack of reliable data to support the long-term efficacy of the combined effect. It is hoped that more scientific evidence-based medical evidence can be provided in the future, including time after stroke occurrence, frequency of treatment, duration of treatment, and follow-up reports.

## Funding

If any, should be placed before the references section without numbering.

#### **Data Availability**

Data sharing is not applicable to this article as no new data were created or analysed in this

study.

# **Conflict of Interest**

The author states that this article has no conflict of interest.

# References

- [1]Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021;20, 795-820.
- [2]Wang, K., Dong, Q., Yu, J.T., and Hu, P. P. Expert Consensus on the Management of post-stroke cognitive impairment 2021. Chin J Stroke2021;16, 376-389.
- [3]Pinter, D., Enzinger, C., Gattringer, T., Eppinger, S., Niederkorn, K., Horner, S., et al. Prevalence and short-term changes of cognitive dysfunction in young ischaemic stroke patients. Eur J Neurol2019; 26, 727-732.
- [4]Sexton, E., McLoughlin, A., Williams, D.J., Merriman, N.A., Donnelly, N., Rohde, D., et al. Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke. Eur Stroke J2019; 4, 160-171.
- [5]Kwon, H.S., Lee, D., Lee, M.H., Yu, S., Lim, J.S., Yu, K.H., et al. Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. J Neurol2020;267, 688-693.
- [6]Yuan, H. W., Liu, Y. X., Zhang, H., Liu, Y., Li, X. L., and Ni, J. X. Tongdu Xingshen acupuncture and moxibustion combined with cognitive training in treatment of post-stroke mild cognitive impairment: a randomized controlled trial. Zhong guo zhen jiu 2022; 42, 839-843
- [7]Wei, B. X, Liu, G. C., and Zeng, J. Y. Clinical observation of Kinesiotherapy-Combined scalp acupuncture combined with cognitive function training in the treatment of post-stroke cognitive impairment. Journal of Guangzhou University of Traditional Chinese Medicine 2023;40,368-374
- [8]Zhang, Y., Tang, W., Song, X. G., et al. Systematical review and meta analysis of the efficacy of acupuncture and moxibustion plus cognitive rehabilitation training in treating post-stroke cognitive disorder. Shanghai J Acu-mox 2015;34, 1013-1020
- [9]Sarker SJ, Rudd AG, Douiri A, Wolfe CD.Comparison of 2 extended activities of daily living scales with the Barthel Index and predictors of their outcomes: cohort study within the South London Stroke Register (SLSR). Stroke 2012;43, 1362-1369
- [10]Kawano, H., Johno, T., Torii, M., Kamiyama, H., Amano, T., Honda, Y., et al. Predictable Value of Functional Independence Measure Differs between Anterior and Posterior Circulation Ischemic Strokes. Eur Neurol 2018; 80, 313-320
- [11]Wu, Y. Y., and Bian, H. Progress in post-stroke cognitive impairment. J Neurol Neurorehabil 2020;16, 34-40
- [12]Rost, N.S., Brodtmann, A., Pase, M.P., van Veluw, S.J., Biffi, A., Duering, M., et al. Post-Stroke Cognitive Impairment and Dementia. Circ Res 2022;130, 1252-1271
- [13]Wang, J. Expert consensus on prevention and treatment of post-stroke cognitive impairment in China.Chin J Stroke 2022;15, 158-166
- [14]Nie, P., Liu, F., Lin, S., Guo, J., Chen, X., Chen, S., et al. The effects of computer-assisted cognitive rehabilitation on cognitive impairment after stroke: A systematic review and meta-analysis. J Clin Nurs 2022;31, [15]Ma, Q., Tang, M. K., and Sun, W.Y. Review of modern research on pathogenesis of TCM of vascular dementia. CJTCMP 2018;33, 212-215

- [16]Xiao, L.Y., Wang, X.R., Yang, J.W., Ye, Y., Zhu, W., Cao, Y., et al. Acupuncture Prevents the Impairment of Hippocampal LTP Through β1-AR in Vascular Dementia Rats. Mol Neurobiol 2018;55, 7677-7690
- [17]Yang, J.W., Wang, X.R., Zhang, M., Xiao, L.Y., Zhu, W., Ji, C.S., et al. Acupuncture as a multifunctional neuroprotective therapy ameliorates cognitive impairment in a rat model of vascular dementia: A quantitative iTRAQ proteomics study. CNS Neurosci Ther 2018;24, 1264-1274
- [18]Li, C. J., Chen, W. Y., and Wang, X. J. Effect of acupuncture combined with butylphthalide capsule and computer aided cognitive rehabilitation training on cognitive dysfunction after stroke. Liaoning Journal of Traditional Chinese Medicine 2020;1000-1719
- [19]Liu, S., Luo, J., Liu, Y. Z. Effect of "Yizhi Kaiqiao" acupuncture on cognitive dysfunction and Cerebral hemodynamics in Stroke Patients. JCAM.Feb 2021; 37, 36-39
- [20]Liu H, Chen L, Zhang G, et al. Scalp Acupuncture Enhances the Functional Connectivity of Visual and Cognitive-Motor Function Network of Patients with Acute Ischemic Stroke. Evid Based Complement Alternat Med 2020;8836794
- [21]Lu,J., Shen, H. Q., Han, L.H, and Ma, G.L. Observations on the Efficacy of Acupuncture plus Cognitive Training for Mild to Moderate Cognitive Disorder in Ischemic Stroke. Shanghai J Acu-mox 2022;41, 686-690
- [22]Wang, Y., Bai, Y. J., Zhang, M., et al. Tongduxingshen acupuncture improves the cognitive function and psycho-behavioral symptoms in patients with post-stroke mild cognitive impairment. Chinese General Practice 2021;24, 4223-4228
- [23]Xiong, J., Zhang, Z., Ma, Y., Li, Z., Zhou, F., Qiao, N., et al. The effect of combined scalp acupuncture and cognitive training in patients with stroke on cognitive and motor functions. NeuroRehabilitation 2020;46, 75-821136-1148